Scarica l'app Stockscreener
64.04
1.83%
1.15
Dopo l'orario di chiusura:
64.04
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HALO Giù?
Forum
Previsione
Precedente Chiudi:
$62.89
Aprire:
$62.68
Volume 24 ore:
2.38M
Relative Volume:
0.95
Capitalizzazione di mercato:
$7.49M
Reddito:
$947.36M
Utile/perdita netta:
$392.47M
Rapporto P/E:
21.21
EPS:
3.02
Flusso di cassa netto:
$392.71M
1 W Prestazione:
+5.31%
1M Prestazione:
+12.06%
6M Prestazione:
+10.20%
1 anno Prestazione:
+14.21%
Intervallo 1D:
$62.68
$64.32
Intervallo di 1 settimana:
$61.27
$65.40
Portata 52W:
$42.01
$70.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Nome
Halozyme Therapeutics Inc
Settore
Industria
Telefono
(858) 794-8889
Indirizzo
12390 EL CAMINO REAL, SAN DIEGO, CA
Confronta HALO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
64.04 | 7.36B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-06 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-05-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Downgrade | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-06-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | Iniziato | TD Cowen | Outperform |
| 2023-07-24 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-24 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Ripresa | Berenberg | Buy |
| 2023-03-16 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | Ripresa | Morgan Stanley | Overweight |
| 2022-11-28 | Iniziato | Wells Fargo | Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2021-06-14 | Iniziato | Evercore ISI | Outperform |
| 2021-05-17 | Iniziato | SVB Leerink | Outperform |
| 2021-05-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | Reiterato | The Benchmark Company | Buy |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-07-01 | Iniziato | The Benchmark Company | Buy |
| 2020-02-05 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | Iniziato | Goldman | Buy |
| 2019-11-05 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-10-19 | Ripresa | Piper Jaffray | Neutral |
| 2018-05-11 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-24 | Iniziato | Goldman | Neutral |
| 2017-10-16 | Reiterato | Piper Jaffray | Overweight |
| 2017-01-06 | Downgrade | Citigroup | Buy → Neutral |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2015-12-04 | Iniziato | Wells Fargo | Outperform |
| 2015-11-18 | Iniziato | Citigroup | Buy |
| 2015-09-22 | Iniziato | Barclays | Overweight |
| 2015-06-22 | Reiterato | JP Morgan | Overweight |
| 2015-03-03 | Reiterato | UBS | Buy |
| 2015-02-18 | Reiterato | MLV & Co | Buy |
| 2015-01-08 | Reiterato | MLV & Co | Buy |
Mostra tutto
Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie
Recovery Signals Appearing in Halozyme Therapeutics Inc. ChartsEarly Entry Tips With Low Risk Zone Shared - 선데이타임즈
What makes Halozyme Therapeutics Inc. stock price move sharplyHigh Performance Equity Ideas - thegnnews.com
Halozyme up after guidance raise, Morgan Stanley upgrade - MSN
H.C. Wainwright Lifts PT on Halozyme Therapeutics (HALO) to $75 From $72 - MSN
Here’s Why Halozyme Therapeutics (HALO) Traded Town in Q2 - Insider Monkey
Halozyme stock price target raised to $56 by Goldman Sachs on IRA impact analysis - Investing.com Canada
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term - sharewise.com
Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $63.00 at JPMorgan Chase & Co. - MarketBeat
J&J, Halozyme cut at Leerink on price control risk for combo products - MSN
Is Halozyme Therapeutics Inc. part of any ETF3x Gain Trade Candidates - thegnnews.com
HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View - MSN
Leerink Partners Maintains Sell Rating on Halozyme with $51 Price Target - AInvest
After Golden Cross, Halozyme Therapeutics (HALO)'s Technical Outlook is Bright - Yahoo Finance
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance
Why Have Halozyme Stocks Plummeted? - TipRanks
What Does the Market Think About Halozyme Therapeutics? - 富途牛牛
A Quick Look at Today's Ratings for Halozyme Therapeutics(HALO.US), With a Forecast Between $75 to $91 - 富途牛牛
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q2 2025 Earnings Call Transcript - Insider Monkey
Results: Halozyme Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - 富途牛牛
HC Wainwright Raises Price Target for Halozyme Therapeutics to $75 - AInvest
Halozyme raises 2025 revenue guidance to $1.355B amid accelerating royalty growth and new product catalysts - MSN
Halozyme Therapeutics’ Earnings Call Highlights Robust Growth - TipRanks
Halozyme Therapeutics Surges on 86.74% Volume Spike to $360M, 329th Market Activity as Royalty Revenue Drives 41% EBITDA Jump - AInvest
Halozyme Therapeutics 2025 Q2 Earnings Surpasses Expectations, Net Income Surges 77% - AInvest
Halozyme Therapeutics (HALO): A High-Conviction Buy as Royalty-Driven Growth Accelerates - AInvest
Halozyme Therapeutics Lifts Outlook As Royalties Climb Higher - Finimize
Halozyme (HALO) Surges on Upgraded Guidance and Increased Revenue - GuruFocus
HALO: JMP Securities Raises Price Target Despite Maintaining "Ma - GuruFocus
Halozyme up after guidance raise, Morgan Stanley upgrade (HALO) - Seeking Alpha
Halozyme Therapeutics: JMP Securities Raises PT to $91 from $78, Maintains Market Outperform - AInvest
Halozyme Therapeutics Guidance Upgrade Driven by Robust Royalty Revenue, Morgan Stanley Says - MarketScreener
HALO Analyst Rating: HC Wainwright Maintains 'Buy' and Raises Pr - GuruFocus
Morgan Stanley Upgrades Halozyme Therapeutics (HALO) to Overweig - GuruFocus
Halozyme Therapeutics 2025 Q2 Earnings Surpasses Expectations with Net Income Jumping 77.1% - AInvest
Morgan Stanley Upgrades Halozyme Therapeutics to Overweight From Equalweight, Raises Price Target to $75 From $62 - MarketScreener
Halozyme Sees Price Target Boost Amid Strong Q2 Performance: Analyst Increases Target to $75, Maintains Buy Rating - AInvest
Halozyme (HALO) Sees Price Target Boost Amid Strong Q2 Performan - GuruFocus
Halozyme Therapeutics: A Masterclass in Platform-Driven Royalty Growth and Strategic Scalability - AInvest
Halozyme Therapeutics Reports Strong Q2 Earnings, Surpassing ExpectationsNews and Statistics - IndexBox
Halozyme Therapeutics: A High-Conviction Buy in the IP-Driven Biotech Revolution - AInvest
Halozyme (HALO) Reports Record Q2 Revenue and Boosts 2025 Guidan - GuruFocus
Halozyme's Q2 2025: Unpacking Contradictions in Patent Litigation, ENHANZE Impact, and Regulatory Challenges - AInvest
Why Halozyme Shares Are Moving Amid Strong Earnings - TipRanks
Halozyme (HALO) Receives Upgrade and Raised Price Target from Mo - GuruFocus
Halozyme Therapeutics stock price target raised to $91 by Citizens JMP - Investing.com Australia
Morgan Stanley upgrades Halozyme stock to Overweight on ORPHAN Cures Act - Investing.com Nigeria
Morgan Stanley upgrades Halozyme stock to Overweight on ORPHAN Cures Act By Investing.com - Investing.com South Africa
Halozyme Therapeutics: Q2 Earnings Snapshot - New Haven Register
Halozyme Therapeutics Inc (HALO) Q2 2025 Earnings Call Highlights: Record Revenue Growth and ... - Yahoo Finance
Halozyme Therapeutics Inc (HALO) Q2 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives - GuruFocus
Halozyme Therapeutics Inc Azioni (HALO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):